IL181573A0 - Muteins of fibroblast growth factor 21 - Google Patents
Muteins of fibroblast growth factor 21Info
- Publication number
- IL181573A0 IL181573A0 IL181573A IL18157307A IL181573A0 IL 181573 A0 IL181573 A0 IL 181573A0 IL 181573 A IL181573 A IL 181573A IL 18157307 A IL18157307 A IL 18157307A IL 181573 A0 IL181573 A0 IL 181573A0
- Authority
- IL
- Israel
- Prior art keywords
- muteins
- growth factor
- fibroblast growth
- nucleic acid
- disclosed
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 230000004989 O-glycosylation Effects 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Child & Adolescent Psychology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60680504P | 2004-09-02 | 2004-09-02 | |
| PCT/US2005/026398 WO2006028595A2 (en) | 2004-09-02 | 2005-07-26 | Muteins of fibroblast growth factor 21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL181573A0 true IL181573A0 (en) | 2007-07-04 |
Family
ID=36036790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL181573A IL181573A0 (en) | 2004-09-02 | 2007-02-26 | Muteins of fibroblast growth factor 21 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7582607B2 (enExample) |
| EP (2) | EP1789442B1 (enExample) |
| JP (1) | JP4809352B2 (enExample) |
| KR (1) | KR100854198B1 (enExample) |
| CN (1) | CN101010338B (enExample) |
| AT (1) | ATE444307T1 (enExample) |
| AU (1) | AU2005283025B2 (enExample) |
| BR (1) | BRPI0514790A (enExample) |
| CA (1) | CA2575753A1 (enExample) |
| DE (1) | DE602005016946D1 (enExample) |
| DK (1) | DK1789442T3 (enExample) |
| EA (1) | EA011390B1 (enExample) |
| ES (1) | ES2332057T3 (enExample) |
| HR (1) | HRP20090597T1 (enExample) |
| IL (1) | IL181573A0 (enExample) |
| MX (1) | MX2007002616A (enExample) |
| NO (1) | NO20071327L (enExample) |
| PL (1) | PL1789442T3 (enExample) |
| PT (1) | PT1789442E (enExample) |
| SI (1) | SI1789442T1 (enExample) |
| WO (1) | WO2006028595A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP2008507294A (ja) | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EP2615172A1 (en) | 2007-04-27 | 2013-07-17 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EP2185178B1 (en) * | 2007-08-03 | 2017-08-23 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2358749B1 (en) * | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| US9120871B2 (en) | 2009-01-23 | 2015-09-01 | Novo Nordisk A/S | Process for preparing FGF21 with low degree of O-glycosylation |
| CN102361647B (zh) | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
| BRPI1011404B1 (pt) * | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| AU2010246038A1 (en) * | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| WO2011154349A2 (en) | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| EP2443145A1 (en) | 2009-06-17 | 2012-04-25 | Amgen, Inc | Chimeric fgf19 polypeptides and uses thereof |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| JP2013512672A (ja) * | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質 |
| UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| ES2543634T3 (es) * | 2010-01-22 | 2015-08-20 | Novo Nordisk A/S | Proceso para preparación de FGF-21 con grado de O-glicosilación bajo |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| EP2558115B1 (en) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
| US9655974B2 (en) | 2010-07-20 | 2017-05-23 | Novo Nordisk A/S | N-terminal modified FGF21 compounds |
| RU2013118441A (ru) | 2010-11-05 | 2014-12-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антидиабетические соединения |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| TWI593708B (zh) * | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI560202B (en) | 2011-12-22 | 2016-12-01 | Pfizer | Anti-diabetic compounds |
| PL2814844T3 (pl) | 2012-02-15 | 2017-12-29 | Novo Nordisk A/S | Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1) |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| EP3456742A1 (en) | 2012-02-15 | 2019-03-20 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
| WO2013131091A1 (en) | 2012-03-02 | 2013-09-06 | New York University | Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders |
| US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| CN104364261B (zh) | 2012-06-11 | 2017-04-05 | 伊莱利利公司 | 成纤维细胞生长因子21变体 |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| CN105828833A (zh) | 2013-10-21 | 2016-08-03 | 萨克生物研究学院 | 突变的成纤维细胞生长因子（fgf）1及使用方法 |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| KR20250110365A (ko) | 2014-07-17 | 2025-07-18 | 노보 노르디스크 에이/에스 | 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발 |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR102427527B1 (ko) | 2014-12-23 | 2022-08-01 | 노보 노르디스크 에이/에스 | Fgf21 유도체 및 그것의 용도 |
| US11638745B2 (en) | 2015-05-20 | 2023-05-02 | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education | Method to improve neurologic outcomes in temperature managed patients |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EP3368059A4 (en) | 2015-10-30 | 2019-03-27 | Salk Institute for Biological Studies | TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| ES3014984T3 (en) | 2017-03-14 | 2025-04-28 | Sunshine Lake Pharma Co Ltd | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| CN111518770B (zh) | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
| CN110128525B (zh) * | 2018-02-08 | 2022-08-26 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
| CR20250022A (es) | 2018-04-02 | 2025-02-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450) |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| JP2023501515A (ja) * | 2019-11-12 | 2023-01-18 | テクニッシェ ウニヴェルズィテート ミュンヘン | ヒトＩＬ－２７αサブユニットの均質ムテイン |
| US20220016211A1 (en) | 2020-01-08 | 2022-01-20 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| CN113633756A (zh) * | 2021-06-17 | 2021-11-12 | 温州医科大学 | Fgf21温敏缓释载体和基因修饰方法以及其制备方法 |
| EP4288461A4 (en) | 2021-07-14 | 2025-07-02 | Beijing Ql Biopharmaceutical Co Ltd | FUSION POLYPEPTIDES FOR METABOLIC DISORDERS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301583D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Yeast strain and methods for expressing heterologous proteins in yeast |
| CA2173750C (en) * | 1994-08-12 | 2011-03-22 | Irving Boime | Single-chain forms of the glycoprotein hormone quartet |
| JP4334615B2 (ja) * | 1994-08-12 | 2009-09-30 | ワシントン・ユニバーシティ | 糖タンパク質ホルモンカルテットの一本鎖形態 |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU7368100A (en) | 1999-09-10 | 2001-04-10 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
| DE60043197D1 (enExample) * | 1999-11-18 | 2009-12-03 | Univ Kyoto | |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| WO2001038357A2 (en) | 1999-11-22 | 2001-05-31 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
| US20040259780A1 (en) * | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| JP2005519891A (ja) | 2002-01-15 | 2005-07-07 | イーライ・リリー・アンド・カンパニー | 危篤状態の患者における罹病率および死亡率を低下させる方法 |
| CA2549249A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
-
2005
- 2005-07-26 AT AT05775749T patent/ATE444307T1/de active
- 2005-07-26 BR BRPI0514790-5A patent/BRPI0514790A/pt not_active IP Right Cessation
- 2005-07-26 PL PL05775749T patent/PL1789442T3/pl unknown
- 2005-07-26 SI SI200530852T patent/SI1789442T1/sl unknown
- 2005-07-26 WO PCT/US2005/026398 patent/WO2006028595A2/en not_active Ceased
- 2005-07-26 EP EP05775749A patent/EP1789442B1/en not_active Expired - Lifetime
- 2005-07-26 KR KR1020077004881A patent/KR100854198B1/ko not_active Expired - Fee Related
- 2005-07-26 US US11/574,332 patent/US7582607B2/en not_active Expired - Fee Related
- 2005-07-26 EA EA200700533A patent/EA011390B1/ru not_active IP Right Cessation
- 2005-07-26 CN CN2005800294803A patent/CN101010338B/zh not_active Expired - Fee Related
- 2005-07-26 AU AU2005283025A patent/AU2005283025B2/en not_active Ceased
- 2005-07-26 JP JP2007529870A patent/JP4809352B2/ja not_active Expired - Fee Related
- 2005-07-26 DE DE602005016946T patent/DE602005016946D1/de not_active Expired - Lifetime
- 2005-07-26 HR HR20090597T patent/HRP20090597T1/hr unknown
- 2005-07-26 PT PT05775749T patent/PT1789442E/pt unknown
- 2005-07-26 ES ES05775749T patent/ES2332057T3/es not_active Expired - Lifetime
- 2005-07-26 DK DK05775749T patent/DK1789442T3/da active
- 2005-07-26 CA CA002575753A patent/CA2575753A1/en not_active Abandoned
- 2005-07-26 EP EP08162741A patent/EP2161281A1/en not_active Withdrawn
- 2005-07-26 MX MX2007002616A patent/MX2007002616A/es active IP Right Grant
-
2007
- 2007-02-26 IL IL181573A patent/IL181573A0/en unknown
- 2007-03-12 NO NO20071327A patent/NO20071327L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4809352B2 (ja) | 2011-11-09 |
| NO20071327L (no) | 2007-05-29 |
| ES2332057T3 (es) | 2010-01-25 |
| EA200700533A1 (ru) | 2007-08-31 |
| CN101010338B (zh) | 2011-06-15 |
| PT1789442E (pt) | 2009-11-11 |
| KR20070050454A (ko) | 2007-05-15 |
| CA2575753A1 (en) | 2006-03-16 |
| BRPI0514790A (pt) | 2008-06-24 |
| EP1789442A2 (en) | 2007-05-30 |
| CN101010338A (zh) | 2007-08-01 |
| ATE444307T1 (de) | 2009-10-15 |
| PL1789442T3 (pl) | 2010-02-26 |
| US7582607B2 (en) | 2009-09-01 |
| DE602005016946D1 (de) | 2009-11-12 |
| SI1789442T1 (sl) | 2010-01-29 |
| HRP20090597T1 (hr) | 2009-12-31 |
| EP2161281A1 (en) | 2010-03-10 |
| DK1789442T3 (da) | 2009-11-16 |
| WO2006028595A2 (en) | 2006-03-16 |
| EA011390B1 (ru) | 2009-02-27 |
| AU2005283025A1 (en) | 2006-03-16 |
| US20080103096A1 (en) | 2008-05-01 |
| WO2006028595A3 (en) | 2007-01-18 |
| AU2005283025B2 (en) | 2011-06-30 |
| KR100854198B1 (ko) | 2008-08-26 |
| JP2008511323A (ja) | 2008-04-17 |
| EP1789442B1 (en) | 2009-09-30 |
| MX2007002616A (es) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL181573A0 (en) | Muteins of fibroblast growth factor 21 | |
| WO2006065582A3 (en) | Muteins of fibroblast growth factor 21 | |
| WO2002068470A3 (en) | Interferon-alpha induced gene | |
| ATE430197T1 (de) | Fibroblasten wachstumsfaktor-ähnliche polypeptide | |
| WO2006081190A3 (en) | Compositions and methods for treating cardiac conditions | |
| EP2851422A3 (en) | CD34neg stem cells for the treatment of gastrointestinal disorders | |
| IL197339A0 (en) | Recombinant uricase protein | |
| WO2006119987A3 (en) | Recombinant n-glycosylated proteins from procaryotic cells | |
| WO2001098491A3 (en) | Osteolevin gene polymorphisms | |
| WO2005095450A3 (en) | Therapeutic use of a growth factor, nsg33 | |
| WO2003008449A8 (en) | Ntb-a, a surface molecule involved in natural killer cells activity | |
| DE60039677D1 (de) | Akt-3 nukleinsäure, polypeptide und deren verwendung | |
| WO2004081043A3 (en) | Baff mutants with at least one amino acid substitution and methods of their production | |
| WO2003033723A3 (en) | Vectors for expressing multiple transgenes | |
| EP2447369A3 (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity | |
| WO2006083516A3 (en) | Modified cyanovirin-n polypeptide | |
| WO2006046073A3 (en) | C1q related protein | |
| WO2006053134A3 (en) | Deamidated interferon-beta | |
| SI1673391T1 (sl) | Modificirana cDNA za visoke ekspresijske nivoje faktorja VIII in njegovih derivatov | |
| DE602004023340D1 (de) | Onkogen, davon abgeleitetes rekombinantes Protein und dessen Verwendung | |
| WO2002058716A3 (en) | Treatment of inflammatory bowel disease using growth factors | |
| WO2005035564A3 (en) | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders | |
| WO2002048182A3 (en) | Interferon-alpha induced gene | |
| ATE423200T1 (de) | Neues plexin-polypeptid, dieses codierende dna und verwendung davon | |
| EP0787798A3 (en) | GRP17 gene |